Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10577.144 | 0.8672 | 0.7223 | 0.9534 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10577.144 | 0.8322 | 0.6495 | 0.9534 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10577.144 | 0.7956 | 0.5735 | 0.9534 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10577.144 | 0.7901 | 0.5621 | 0.9534 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10577.144 | 0.7696 | 0.5196 | 0.9534 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 10577.144 | 0.0423 | -0.9275 | 0.9534 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 10937.144 | 0.9460 | 0.9295 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 10937.144 | 1.0046 | 1.0059 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10937.144 | 0.9382 | 0.9192 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10937.144 | 0.8176 | 0.7558 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10937.144 | 0.7605 | 0.6755 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10937.144 | 0.7033 | 0.5929 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10937.144 | 0.7137 | 0.6081 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10937.144 | 0.6574 | 0.5250 | 1.5466 | |
| HCC3153 | TNBC | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 10937.144 | 0.0113 | -0.8900 | 1.5466 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 10578.144 | 0.7987 | 0.7436 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 10578.144 | 0.7295 | 0.6497 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10578.144 | 0.6383 | 0.5204 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10578.144 | 0.6774 | 0.5766 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10578.144 | 0.6309 | 0.5097 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10578.144 | 0.6205 | 0.4943 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10578.144 | 0.6325 | 0.5121 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10578.144 | 0.5609 | 0.4051 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 133 | uM | 10578.144 | 0.0076 | -0.8988 | 1.6376 | |
| HCC38 | TNBC | Basal B | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 11850.144 | 0.8862 | 0.8791 | 1.9379 |